

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)



(10) International Publication Number
WO 2021/155300 A3

(51) International Patent Classification:
G01N 33/574 (2006.01) G01N 33/68 (2006.01)
(21) International Application Number:
PCT/US2021/015915

(22) International Filing Date:
29 January 2021 (29.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/968,941 31 January 2020 (31.01.2020) US

(71) Applicant: **VENN BIOSCIENCES CORPORATION**
[US/US]; Two Tower place, 5th floor, South San Francisco,
California 94080 (US).

(72) Inventors: **XU, Gege**; c/o Venn Biosciences Corporation,
Two Tower place, 5th floor, South San Francisco, California
94080 (US). **SHEN, Ling**; c/o Venn Biosciences Corpora-
tion, Two Tower place, 5th floor, South San Francisco, Cal-
ifornia 94080 (US). **XU, Hui**; c/o Venn Biosciences Cor-
poration, Two Tower place, 5th floor, South San Francis-
co, California 94080 (US). **SERIE, Daniel**; c/o Venn Bio-
sciences Corporation, Two Tower place, 5th floor, South
San Francisco, California 94080 (US).

(74) Agent: **HAN, EunHee** et al.; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: BIOMARKERS FOR DIAGNOSING OVARIAN CANCER




Figure 1

(57) Abstract: Set forth herein are glycopeptide biomarkers useful for diagnosing diseases and conditions, such as but not limited to, cancer (e.g., ovarian), an autoimmune disease, fibrosis and aging conditions. Also set forth herein are methods of generating glycopeptide biomarkers and methods of analyzing glycopeptides using mass spectroscopy. Also set forth herein are methods of analyzing glycopeptides using machine learning algorithms.

WO 2021/155300 A3

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

10 September 2021 (10.09.2021)